Recent News

• 09.18.2025 - New Phase 1 Results In Metastatic Melanoma
• 09.18.2025 - New Phase 1 Results In Metastatic Melanoma
• 09.17.2025 - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
• 09.17.2025 - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
• 09.12.2025 - Voting Rights and Shares Capital of the Company
• 09.12.2025 - Voting Rights and Shares Capital of the Company
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Recent Filings

• 09.17.2025 - EX-99.1 EX-99.1
• 09.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.12.2025 - EX-99.1 EX-99.1
• 09.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2025 - EX-99.1 EX-99.1
• 08.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]